These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

54 related articles for article (PubMed ID: 566675)

  • 21. Effect of L-dopa on plasma renin activity with and without inhibition of extracerebral dopa decarboxylase in dogs.
    Blair ML; Reid IA; Ganong WF
    J Pharmacol Exp Ther; 1977 Jul; 202(1):209-15. PubMed ID: 874815
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Genetic inactivation of dopamine D1 but not D2 receptors inhibits L-DOPA-induced dyskinesia and histone activation.
    Darmopil S; Martín AB; De Diego IR; Ares S; Moratalla R
    Biol Psychiatry; 2009 Sep; 66(6):603-13. PubMed ID: 19520364
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effect of L-dopa on exploratory activity after catecholamine receptors blocking agents.
    Maj J; Pawlowski L
    Pol J Pharmacol Pharm; 1974; 26(6):633-8. PubMed ID: 4445053
    [No Abstract]   [Full Text] [Related]  

  • 24. Antidepressant activities of WEB 1881, a new nootropic agent.
    Maj J; Rogóz Z; Skuza G; Sowińska H; Nowak G
    Pol J Pharmacol Pharm; 1989; 41(5):439-52. PubMed ID: 2561889
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Actions at sites other than D(3) receptors mediate the effects of BP897 on l-DOPA-induced hyperactivity in monoamine-depleted rats.
    Visanji NP; Millan MJ; Brotchie JM
    Exp Neurol; 2006 Nov; 202(1):85-92. PubMed ID: 16814282
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Preliminary pharmacological evaluation of newly synthesized derivatives of phosphonoamino acids.
    Kleinrok Z; Kolasa K; Mastalerz P; Kafarski P
    Pol J Pharmacol Pharm; 1986; 38(5-6):435-42. PubMed ID: 3575164
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The monoamine reuptake inhibitor BTS 74 398 fails to evoke established dyskinesia but does not synergise with levodopa in MPTP-treated primates.
    Hansard MJ; Smith LA; Jackson MJ; Cheetham SC; Jenner P
    Mov Disord; 2004 Jan; 19(1):15-21. PubMed ID: 14743355
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The antiparkinsonian drug budipine stimulates the activity of aromatic L-amino acid decarboxylase and enhances L-DOPA-induced dopamine release in rat substantia nigra.
    Biggs CS; Fisher A; Starr MS
    Synapse; 1998 Nov; 30(3):309-17. PubMed ID: 9776134
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Transition-state analogues as inhibitors of L-dopa decarboxylase.
    Brinkworth RI; Iles MM; Iskander MN; Andrews PR
    Int J Biochem; 1988; 20(11):1273-9. PubMed ID: 3248681
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Alpha1-adrenoceptors mediate dihydroxyphenylalanine-induced activity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaques.
    Visanji NP; Fox SH; Johnston TH; Millan MJ; Brotchie JM
    J Pharmacol Exp Ther; 2009 Jan; 328(1):276-83. PubMed ID: 18955589
    [TBL] [Abstract][Full Text] [Related]  

  • 31. ERK phosphorylation and FosB expression are associated with L-DOPA-induced dyskinesia in hemiparkinsonian mice.
    Pavón N; Martín AB; Mendialdua A; Moratalla R
    Biol Psychiatry; 2006 Jan; 59(1):64-74. PubMed ID: 16139809
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The parkinsonian neurotoxin 1-methyl-4-phenylpyridinium (MPP(+)) mediates release of l-3,4-dihydroxyphenylalanine (l-DOPA) and inhibition of l-DOPA decarboxylase in the rat striatum: a microdialysis study.
    Foster SB; Wrona MZ; Han J; Dryhurst G
    Chem Res Toxicol; 2003 Oct; 16(10):1372-84. PubMed ID: 14565778
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Restorative effects of glutamate antagonists in experimental parkinsonism.
    Archer T; Palomo T; Fredriksson A
    Amino Acids; 2002; 23(1-3):71-85. PubMed ID: 12373521
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Psychopharmacological profile of mesterolone.
    Baran L; Przegaliński E
    Pol J Pharmacol Pharm; 1981 Oct; 33(3):299-303. PubMed ID: 7198778
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Proceedings: Hypoglycaemic action of l-DOPA in nialamide treated mice.
    Darwish SA; Furman BL
    Br J Pharmacol; 1975 Jun; 54(2):263P. PubMed ID: 125131
    [No Abstract]   [Full Text] [Related]  

  • 36. L-Dopa methyl ester: prolongation of survival of neuroblastoma-bearing mice after treatment.
    Wick MM
    Science; 1978 Feb; 199(4330):775-6. PubMed ID: 622565
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Caesium ion: antagonism to chlorpromazine- and L-dopa- produced behavioural depression in mice.
    Messina FS
    J Pharm Pharmacol; 1975 Nov; 27(11):873-4. PubMed ID: 1502
    [No Abstract]   [Full Text] [Related]  

  • 38. [Action of different inhibitors of L-DOPA decarboxylase on the water ration, diuresis and urinary sodium and potassium elimination in rats].
    BARRE N; CAHN J; HEROLD M
    C R Seances Soc Biol Fil; 1962; 156():1807-9. PubMed ID: 13969508
    [No Abstract]   [Full Text] [Related]  

  • 39. Antagonistic effect of lithium chloride on l-dopa-induced locomotor activity in rats.
    Smith DF
    Pharmacol Res Commun; 1976 Dec; 8(6):575-9. PubMed ID: 1026976
    [No Abstract]   [Full Text] [Related]  

  • 40. [The pharmacology of 3,4-dihydroxyphenyl-alpha-hydroxypropionic acid sodium salt].
    Uspenskiĭ AE
    Farmakol Toksikol; 1978; 41(4):418-20. PubMed ID: 566675
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.